I suggest selling the July Chemours call options (recommended in March) as the expiration is looming and the stock showing little chance of closing well above the $50 strike price. I still like the prospects of Chemours and believe the October call options should give enough time for the bull story to play out. Read More

Tariff fears have dragged down the Chemours (NYSE: CC) enough that the July $50 calls are not likely to recoup much of their losses before the expiration date. I suggest selling these for a small portion of our purchase price and using those proceeds to buy the October series. See my buy alert for the October $49 calls under a separate alert. Read More

I am keeping Tapestry (NYSE: TPR) in the portfolio as a long but suggest selling these call options which have doubled in two weeks time. Read More

Sell the July Omnicom puts today. I hate booking a loss but a negative initiation by MoffettNathanson will hopefully lift the price a bit.  Read More

PRA Health has had a terrific run in the past month without a coincident increase in estimates. The stock hit my target and I cannot justify a higher one. The fundamentals are sound on the stock, this is a pure valuation call. Read More